What is it about?
This research explores the biological mechanisms that trigger Parkinson's disease, specifically focusing on the formation of Lewy bodies. Recently, it was discovered that Lewy bodies are primarily composed of membrane fragments and lipids, lacking the alpha-synuclein fibrils that scientists long believed were their main ingredient. To explain this missing ingredient, we developed a mathematical model simulating the transport and aggregation of proteins inside neurons. Our model tests the hypothesis that misfolded alpha-synuclein acts as a catalyst—speeding up the clumping of cellular membranes to form Lewy bodies without actually getting trapped inside them.
Featured Image
Photo by Jose Antonio Rodriguez Davia on Unsplash
Why is it important?
This work provides a timely explanation for the exceptionally long premotor phase of Parkinson's disease, which often spans decades. By modeling a two-step process—first the slow formation of alpha-synuclein oligomers, followed by the clustering of cellular organelles—we can explain why the disease takes so long to manifest clinically. Crucially, our findings suggest a major shift in how we might treat the disease. Because the formation of Lewy bodies becomes an autocatalytic, self-sustaining process, clearing alpha-synuclein from the brain after Lewy bodies have already started forming may fail to stop the disease's progression. This underscores the critical need for early detection and intervention strategies.
Perspectives
Developing this model alongside my co-author, Ivan, was a deeply rewarding challenge. We wanted to build a mathematical bridge between the latest, somewhat controversial microscopic findings and the macroscopic progression of a devastating disease. It is fascinating to see how applying chemical kinetics can completely reframe our understanding of neurodegeneration. I am particularly struck by the implications for future clinical trials. Witnessing the failure of late-stage therapies in neurodegenerative diseases has been frustrating for the medical community. I hope our modeling work encourages a pivot toward earlier diagnostics, saving researchers from chasing therapeutic targets that have already outlived their catalytic role.
Andrey V Kuznetsov
North Carolina State University
Read the Original
This page is a summary of: Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?, Mathematical Biosciences, February 2022, Elsevier,
DOI: 10.1016/j.mbs.2021.108754.
You can read the full text:
Contributors
The following have contributed to this page
